ArticleInternational journal of clinical pediatric dentistry2025
Evaluation of Structural Characterization and Biocompatibility of Glass Ionomer Cement Enhanced with Nanocomposites of Chitosan, Titanium, Zirconium, and Hydroxyapatite: Assessment of Cell Viability and Adhesion through Gingival Fibroblast Cell Line.
Article in International journal of clinical pediatric dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surface Roughness and Color Stability of Conventional Glass Ionomer Cement Reinforced With a Nanofiller Synthesized by the Coprecipitation Method.International journal of biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate the structural characterization and biocompatibility of novel glass ionomer cement (GIC) enhanced with a nanocomposite of chitosan, titanium, zirconium, and hydroxyapatite. Materials and methods: The experimental GIC was formulated by incorporating chitosan, titanium, zirconium, and hydroxyapatite nanoparticles into the conventional GIC matrix. The modified GIC was analyzed using scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), and X-ray diffraction (XRD) to assess the integration of the nanocomposite and its effects on the microstructure. Fibroblast cell viability was evaluated on GIC composite disks compared to conventional GIC. Fluorescence microscopy was performed to assess cell viability and morphology. SEM was used to evaluate fibroblast attachment and morphology on the experimental GIC surfaces. The obtained data were statistically analyzed using one-way analysis of variance (ANOVA) to determine significant differences between groups. Results: X-ray diffraction confirmed the successful incorporation of the nanocomposite components, with evidence of phase stability and homogeneous distribution. FTIR identified strong chemical interactions between the nanocomposite and GIC matrix. SEM revealed reduced porosity and uniform dispersion of nanoparticles, contributing to enhanced structural integrity. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay demonstrated high fibroblast cell viability, comparable to control samples, with no significant cytotoxic effects. Live/dead staining showed a higher proportion of viable cells on the modified GIC, indicating improved biocompatibility. SEM analysis of cell adhesion revealed better attachment and spreading of fibroblasts on the nanocomposite-enhanced GIC. Conclusion: The integration of a chitosan-titanium-zirconium-hydroxyapatite nanocomposite into GIC enhances its mechanical properties, biocompatibility, and bioactivity. This multifunctional material addresses the limitations of conventional GIC and offers potential as a next-generation material. How to cite this article: Muthukumaran V, Paulraj J, Maiti S,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.